新型自体肿瘤细胞疫苗治疗进展期肿瘤患者的免疫学检测

Immunological evaluation of a novel autologous whole tumor cell vaccine for treating patients with advanced tumor

目的 探讨自体肿瘤疫苗的作用机制。方法 2 0例进展期肿瘤患者术后第 4周开始以自体肿瘤细胞疫苗行主动免疫治疗。免疫接种共 4次 ,每次间隔 7～ 10d ;接种前 3d及第 4次接种后一周 ,采集外周血 ,分离单个核细胞 ,以流式细胞分析术 /细胞内细胞因子检测法测定CD8+ IFN γ+ ,CD8+ IL 10 + 细胞及CD4+ IFN γ+ ,CD4+ IL 10 + 细胞 ;同时采集血清 ,ELISA法检测血清IFN γ、IL 10水平。结果 自体肿瘤细胞疫苗治疗后 :①血清IFN γ水平升高 [(7.16± 2 .91)ng·L- 1升至 (11.68± 4.86)ng·L- 1,P <0 .0 5] ;而IL 10水平下降 [2 1.0 4± 13 .81)ng·L- 1降至 (13 .41± 5.71)ng·L- 1,P <0 .0 5] ;②CD8+ IFN γ+ 阳性细胞由 (3 .80± 1.45) %升至 (6.94± 2 .63 ) % ;CD4+ IFN γ+ 阳性细胞由 (3 .0 9± 1.52 ) %升至 (5.2 0± 2 .94) % (P <0 .0 5) ;③病人耐受良好。

Objective To evaluate the immunological parameter s of patients with resected advanced tumor after active immunotherapy using a no vel autologous whole tumor cell vaccine. Methods Twenty pos t-operative patients with advanced tumors were enrolled in this study. The vacc ination was started at 4 weeks after resection to allow the patients sufficient time to recover from immunological suppression induced by surgery. The vaccinati on was in a total 4 weeks scheme with an interval of 7～10 days. Intracellular c ytokine of CD8 +IFN- γ +, CD4 +IFN- γ + , CD4 +IL-10 +, and CD8 +IL-10 T cell in PBMNC were detected b y flow cytometry 3 days before and 7 days after the final inoculation; serum lev el of IFN- γ and IL-10 was assayed by ELISA at the same time. Res ults The serum level of IFN- γ was elevated (7.16±2.91 ng·L -1 vs. 11.68±4.86 ng·L -1 , P <0.05) whereas IL-10 was decl ined (21.04±13.81 ng·L -1 vs. 13.41±5.71 ng·L -1 , P <0.05 ); CD8 +IFN- γ +T cells were increased from (3.80 ±1.45)% to (6.94±2 .63)%; CD4 +IFN- γ +T cells were increased from (3.09±1.52)% to (5.20±2 .94)% ( P < 0.05 ). The patients showed good tolerance. Conclusion Inoculation with autologous tumor vaccine can improve the cell-med iated anti-tumor immuno-response of tumor patients.